Avantor (NYSE:AVTR) Given Outperform Rating at Raymond James

Raymond James restated their outperform rating on shares of Avantor (NYSE:AVTR) in a report released on Monday,Benzinga reports. They currently have a $24.00 price objective on the stock, down from their prior price objective of $26.00.

Several other research firms have also weighed in on AVTR. UBS Group reiterated a “neutral” rating and set a $25.00 target price (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Robert W. Baird reduced their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Stifel Nicolaus reduced their target price on Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a report on Monday. Barclays reduced their target price on Avantor from $26.00 to $23.00 and set an “overweight” rating on the stock in a report on Monday. Finally, Wells Fargo & Company cut their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $26.15.

Avantor Stock Down 0.9 %

Shares of Avantor stock opened at $19.00 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. Avantor has a 12 month low of $18.49 and a 12 month high of $28.00. The business has a fifty day simple moving average of $21.73 and a 200 day simple moving average of $23.47. The stock has a market cap of $12.93 billion, a PE ratio of 41.30, a price-to-earnings-growth ratio of 3.87 and a beta of 1.28.

Avantor (NYSE:AVTR) last posted its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same quarter last year, the firm earned $0.22 EPS. Research analysts predict that Avantor will post 0.98 EPS for the current year.

Institutional Trading of Avantor

Several institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC increased its position in Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after buying an additional 1,285 shares during the last quarter. UMB Bank n.a. acquired a new position in Avantor during the third quarter worth approximately $49,000. Livforsakringsbolaget Skandia Omsesidigt increased its position in Avantor by 278.0% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock worth $130,000 after buying an additional 3,700 shares during the last quarter. Oliver Luxxe Assets LLC increased its position in Avantor by 36.7% during the third quarter. Oliver Luxxe Assets LLC now owns 84,009 shares of the company’s stock worth $2,173,000 after buying an additional 22,534 shares during the last quarter. Finally, ORG Wealth Partners LLC acquired a new position in shares of Avantor in the third quarter valued at approximately $139,000. Institutional investors own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.